Barclays analyst Balaji Prasad lowered the firm’s price target on Pacira (PCRX) to $17 from $25 and keeps an Equal Weight rating on the shares. The company’s Q3 revenue missed consensus by 6%, with Exparel in-line and strong gross margin at 78%, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
Questions or Comments about the article? Write to editor@tipranks.com